carteolol has been researched along with Cardiac Failure in 3 studies
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 5.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "Fifteen patients with congestive heart failure underwent beta-blocker therapy." | 2.68 | Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. ( Akaishi, M; Anzai, T; Baba, A; Handa, S; Mitamura, H; Nishimura, H; Ogawa, S; Yoshikawa, T, 1996) |
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 1.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshikawa, T | 1 |
| Handa, S | 1 |
| Anzai, T | 1 |
| Nishimura, H | 1 |
| Baba, A | 1 |
| Akaishi, M | 1 |
| Mitamura, H | 1 |
| Ogawa, S | 1 |
| Gwathmey, JK | 2 |
| Kim, CS | 1 |
| Hajjar, RJ | 2 |
| Khan, F | 1 |
| DiSalvo, TG | 1 |
| Matsumori, A | 1 |
| Bristow, MR | 1 |
| Washington, B | 1 |
| Butler, K | 1 |
| Doye, AA | 1 |
| Jang, M | 1 |
1 trial available for carteolol and Cardiac Failure
| Article | Year |
|---|---|
Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Arginine Vasopressin; Atrial Natriuretic Factor; Carteolol; Female; Hea | 1996 |
2 other studies available for carteolol and Cardiac Failure
| Article | Year |
|---|---|
Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol.
Topics: Adenosine Triphosphate; Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Blood Pressure; Bod | 1999 |
Heart function challenged with beta-receptor agonism or antagonism in a heart failure model.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Blood Pressure; Ca | 2001 |